Curis

CRIS

Market cap $15.9M

LEXINGTON, Mass. , Nov. 14, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that Curis will report emavusertib and BTKi clinical data in Primary CNS Lymphoma (PCNSL) and Secondary CNS Lymphoma (SCNSL) in three presentations and preclinical data on emavusertib in an oral presentation at the 30th Annual Meeting of the Society for Neuro-Oncology (SNO) on November 19-23: November 21, 2025 – 4:30 PM ET (11:30 AM HT) Format:      Poster Presentation Presenter:    Dr. Christian Grommes, Memorial Sloan Kettering Cancer Center, NY, NY Title: Analysis of Genetic Mutation Profile and CNS Pharmacokinetics in Relapsed/Refractory Primary CNS Lymphoma Patients Responding to Novel Emavusertib (IRAK4i) and BTKi Combination Format:      Poster Presentation Presenter:    Dr. Lakshmi Nayak, Dana-Farber Cancer Institute, Boston, MA Title:              Preliminary Safety and Efficacy of Emavusertib (CA-4948) in Combination with Ibrutinib in Relapsed/Refractory Primary Central Nervous System Lymphoma Patients November 22, 2025 – 4:45 PM ET (11:45 AM HT) Format:      Rapid Oral Presentation Presenter:    Dr. Christian Grommes, Memorial Sloan Kettering Cancer Center, NY, NY Title: Analysis of Genetic Mutation Profile and CNS Pharmacokinetics in Relapsed/Refractory Primary CNS Lymphoma Patients Responding to Novel Emavusertib (IRAK4i) and BTKi Combination Format:        Poster Presentation Presenter:    Cecilia A.

Curis, Inc. ( CRIS ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Diantha Duvall - CFO and Principal Financial & Accounting Officer James Dentzer - President, CEO, Secretary, Treasurer & Director Ahmed Hamdy - Chief Medical Officer Conference Call Participants Sara Nik - H.C. Wainwright & Co, LLC, Research Division Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Yale Jen - Laidlaw & Company (UK) Ltd.

Curis (CRIS) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to a loss of $1.7 per share a year ago.

Management to host conference call and webcast today at 4:30 p.m. ET LEXINGTON, Mass.

LEXINGTON, Mass. , Oct. 30, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2025 financial and operating results on Thursday, November 6, 2025, at 4:00 p.m.

LEXINGTON, Mass. , Oct. 3, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that on October 1, 2025, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 84,750 shares of Curis common stock to two new employees, with a grant date of October 1, 2025 (the "Q4 2025 Inducement Grants").

Curis, Inc. (NASDAQ:CRIS ) Cantor Global Healthcare Conference 2025 September 5, 2025 9:45 AM EDT Company Participants James Dentzer - President, CEO, Secretary, Treasurer & Director Conference Call Participants Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Presentation Li Wang Watsek Research Analyst Hey, everyone. Welcome to our next session with Curis.

Curis, Inc. (NASDAQ:CRIS ) H.C. Wainwright 27th Annual Global Investment Conference September 10, 2025 10:00 AM EDT Company Participants James Dentzer - President, CEO, Secretary, Treasurer & Director Presentation James Dentzer President, CEO, Secretary, Treasurer & Director Good afternoon.

LEXINGTON, Mass. , Sept. 2, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences: The Cantor Global Healthcare Conference 2025 being held September 3 – 5, 2025.

Curis (CRIS 4.38%), a biotechnology company focused on developing targeted cancer therapies, reported its earnings for the second quarter of 2025 on August 5, 2025. Curis reported a GAAP net loss of $0.68 per share, outperforming the analyst expectation of a $1.36 GAAP loss.